Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report

Celeste Witting, Jessica Quaggin-Smith, Ruben Mylvaganam, Graham Peigh, Michael Peter Angarone, James D. Flaherty*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Tocilizumab, an interleukin-6 receptor antagonist, has been used to treat critically ill patients with coronavirus disease-2019. We present the case of a previously immunocompetent man with coronavirus disease-2019 who developed invasive pulmonary aspergillosis after treatment with tocilizumab, illustrating the importance of considering opportunistic infections when providing immune modulating therapy.

Original languageEnglish (US)
Article number115272
JournalDiagnostic Microbiology and Infectious Disease
Volume99
Issue number4
DOIs
StatePublished - Apr 2021

Keywords

  • aspergillosis
  • COVID-19
  • fungal infections
  • opportunistic Infections
  • pulmonary disease
  • tocilizumab

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report'. Together they form a unique fingerprint.

Cite this